At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 10 enrolled
Drug / intervention
Letrozoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
In Brief
A Phase 4 clinical trial evaluating Letrozole for Ovulation Disorder and Ovarian Cysts. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of the study is to establish that sustained estrogen levels are the driving force for the LH surge, and are thereby necessary for ovulation to occur. We predict that by reducing levels of circulating estrogen, letrozole, an aromatase inhibitor, will inhibit ovulation from occurring.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvulation Disorder, Ovarian Cysts
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
Primary CompletionMay 2008
First PostedDec 2013
TodayJul 2026
First PostedDec 3, 2013
Enrollment StartApr 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.6 years ago
Interventions
Letrozoledrug
Letrozole administered daily through the time of ovulation.